Henry Schein, Inc. (NASDAQ:HSIC) Shares Sold by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. lowered its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 42.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 46,187 shares of the company's stock after selling 33,527 shares during the period. Envestnet Asset Management Inc.'s holdings in Henry Schein were worth $3,196,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Barclays PLC boosted its holdings in Henry Schein by 6.9% in the 3rd quarter. Barclays PLC now owns 286,475 shares of the company's stock valued at $20,882,000 after purchasing an additional 18,458 shares during the last quarter. Virtu Financial LLC purchased a new position in Henry Schein in the third quarter worth approximately $239,000. Wilmington Savings Fund Society FSB acquired a new stake in Henry Schein during the third quarter worth $109,000. Tidal Investments LLC raised its position in Henry Schein by 54.9% in the third quarter. Tidal Investments LLC now owns 13,942 shares of the company's stock valued at $1,016,000 after purchasing an additional 4,939 shares during the period. Finally, Franklin Resources Inc. lifted its stake in shares of Henry Schein by 14.0% in the 3rd quarter. Franklin Resources Inc. now owns 37,637 shares of the company's stock valued at $2,673,000 after purchasing an additional 4,621 shares during the last quarter. 96.62% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CEO Bradford C. Connett sold 4,036 shares of the company's stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $71.15, for a total transaction of $287,161.40. Following the completion of the transaction, the chief executive officer now directly owns 62,688 shares of the company's stock, valued at approximately $4,460,251.20. This represents a 6.05 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Philip A. Laskawy sold 2,604 shares of the firm's stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $71.04, for a total value of $184,988.16. Following the sale, the director now directly owns 24,805 shares in the company, valued at $1,762,147.20. This trade represents a 9.50 % decrease in their position. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by company insiders.

Henry Schein Stock Down 1.6 %

Shares of Henry Schein stock traded down $1.06 during trading hours on Friday, reaching $65.17. 736,945 shares of the company were exchanged, compared to its average volume of 1,623,471. The firm has a market cap of $7.98 billion, a PE ratio of 26.82, a PEG ratio of 2.13 and a beta of 0.84. The stock's fifty day moving average is $69.21 and its 200 day moving average is $71.80. Henry Schein, Inc. has a 1 year low of $60.56 and a 1 year high of $82.49. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.82 and a current ratio of 1.42.

Henry Schein (NASDAQ:HSIC - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported $1.19 earnings per share for the quarter, missing the consensus estimate of $1.23 by ($0.04). Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The company had revenue of $3.19 billion for the quarter, compared to analysts' expectations of $3.25 billion. During the same quarter last year, the company earned $0.66 EPS. Henry Schein's revenue for the quarter was up 5.8% compared to the same quarter last year. As a group, equities research analysts forecast that Henry Schein, Inc. will post 4.74 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts recently issued reports on HSIC shares. Jefferies Financial Group raised their price objective on Henry Schein from $77.00 to $80.00 and gave the stock a "hold" rating in a research report on Thursday, January 23rd. Wells Fargo & Company assumed coverage on shares of Henry Schein in a research note on Friday, February 14th. They issued an "equal weight" rating and a $80.00 price target on the stock. Barrington Research restated an "outperform" rating and issued a $90.00 price objective on shares of Henry Schein in a report on Wednesday, February 26th. UBS Group dropped their target price on shares of Henry Schein from $83.00 to $80.00 and set a "neutral" rating for the company in a report on Wednesday, February 26th. Finally, StockNews.com lowered Henry Schein from a "buy" rating to a "hold" rating in a research report on Thursday, April 17th. Six analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Henry Schein currently has a consensus rating of "Moderate Buy" and a consensus target price of $81.10.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.